Evidence supporting the use of: Alpha lipoic acid
For the health condition: Arteriosclerosis

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Alpha lipoic acid (ALA) is an antioxidant compound that has been investigated for its potential cardiovascular benefits, including its use in conditions like arteriosclerosis (the thickening and hardening of arterial walls). The scientific justification for ALA in arteriosclerosis is based primarily on its established roles in reducing oxidative stress, improving endothelial function, and modulating inflammation—all key factors involved in the development and progression of arteriosclerosis.

Several animal and in vitro studies have shown that ALA can reduce oxidative damage to blood vessels, inhibit LDL oxidation (a process central to plaque formation), and improve nitric oxide-mediated vasodilation. Some small clinical trials and meta-analyses suggest that ALA supplementation may improve endothelial function and lower markers of inflammation in people with metabolic syndrome or diabetes, both of which are risk factors for arteriosclerosis.

However, direct evidence from large, high-quality clinical trials specifically evaluating ALA for the prevention or treatment of arteriosclerosis in humans is limited. Most available human studies have focused on surrogate endpoints (such as endothelial function or oxidative stress markers) rather than direct measures of arterial plaque or clinical cardiovascular events. As such, while the mechanistic rationale is strong and early evidence is promising, the overall strength of clinical evidence supporting ALA use specifically for arteriosclerosis remains modest.

In summary, the use of alpha lipoic acid for arteriosclerosis has scientific rationale and some preliminary support, but robust clinical validation is still lacking.

More about alpha lipoic acid
More about Arteriosclerosis